Arpeggio Bio

Arpeggio's core technology integrates a proprietary biological assay with machine learning to create high-resolution snapshots of cellular changes after drug exposure. The company's platform, GRETA™, is an automated system that analyzes nascent RNA—the earliest transcripts from DNA—to observe gene expression changes within minutes of drug application. This allows for the monitoring of over 100,000 transcripts to reconstruct the biological networks affected by a molecule, revealing its mechanism of action. By creating the world's largest database of chemotranscriptomics, Arpeggio aims to identify novel modulators for historically "undruggable" targets like transcription factors, which are often implicated in diseases.

The company's business model has two primary streams. Initially, Arpeggio generated revenue through platform-as-a-service partnerships with over 40 pharmaceutical and biotech companies, including Johnson & Johnson, Novartis, and FORMA Therapeutics. In these collaborations, partners provide compounds for Arpeggio to analyze, and the company sells back the detailed intelligence on the drugs' transcriptomic impact. Secondly, Arpeggio is developing its own internal pipeline of therapeutics. This pipeline is focused on diseases driven by transcriptional dysregulation, such as drug-resistant cancers, chronic kidney disease, and neurodegeneration. Revenue from its own drug assets is expected through co-development partnerships, patent sub-licensing, and royalty arrangements. The company has secured significant funding, including a $3.2 million seed round in 2020 and a $17 million Series A in 2022, to advance both its technology platform and its internal drug pipeline.